Market Overview

Abbott to Collaborate with Janssen Pharma, Pharmacyclics to Develop Companion Test for Investigational Leukemia Therapy

Share:
Related ABT
Earnings Beat Propels Abbott Laboratories To New All-Time High
Abbott Tops Q1 Expectations
Can Mylan (MYL) Specialty Segment Secure Earnings Beat? - Analyst Blog (Zacks)
Related PCYC
Pharmacyclics Shares Fall As Kyle Bass Files Petition To Cancel Patent
CAR-T Therapy Stocks Hit Hard Following AACR Data
Top Stock Mutual Fund New Buys: CyberArk Software (Investor's Business Daily)

Abbott (NYSE: ABT) announced today that it will collaborate with Janssen Biotech, Inc. and Pharmacyclics, Inc. (NASDAQ: PCYC) to explore the benefits of Abbott's proprietary FISH (fluorescence in situ hybridization) technology for use in developing a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.

Under the agreement, Abbott will develop a FISH-based test to identify high-risk CLL patients who have a deletion within a specific chromosome (chromosome 17p (del17p)) and may respond to ibrutinib, an oral, small molecule inhibitor of Bruton tyrosine kinase (BTK). Ibrutinib is currently in development by Janssen and Pharmacyclics for several B-cell malignancies, including chronic leukemia and lymphoma. Patients harboring a deletion within chromosome 17p are poor responders to chemoimmunotherapy and have limited treatment options. Having a test that is able to accurately detect the 17p deletion identifies a specific patient population with a high unmet medical need.

Posted-In: News

 

Related Articles (PCYC + ABT)

Around the Web, We're Loving...

Get Benzinga's Newsletters